US Healthcare Reform and the Pharmaceutical Industry
| Author: | Arthur Daemmrich |
|---|---|
| Published: | October 11, 2011 |
| Paper Release Date: | September 2011 |
| Feature: | Working Papers |
The 2010 Patient Protection and Affordable Care Act (ACA) will restructure the US health care market in the coming years. For the pharmaceutical industry, the ACA is likely to prove a mixed blessing. In this paper, Assistant Professor Arthur Daemmrich analyzes the political economy of health care, specifically concerning health care reform. He then considers how the ACA will affect the pharmaceutical sector, both quantitatively in terms of the size of the prescription drug market and qualitatively in terms of industry structure and competitive dynamics. Daemmrich also places the current reforms into historical context and describes the political negotiations that enabled passage of the ACA.
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
| Published: | January 5, 2011 |
|---|---|
| Feature: | Op-Ed |
| Forum: | open for comment; 6 Comments posted |
Funding unpredictability in human embryonic stem-cell research inflicts a heavy cost on all scientific progress, says professor William Sahlman.
Published in 2009
The Challenges of Investing in Science-Based Innovation
| Published: | June 1, 2009 |
|---|---|
| Feature: | Executive Education |
Smart science-based businesses view today's economic turmoil as an opportunity to stoke up research and innovation for long-term competitive advantage, says professor Vicki L. Sato. How about your business?
Where is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
| Author: | Arthur Daemmrich |
|---|---|
| Published: | April 22, 2009 |
| Paper Release Date: | April 2009 |
| Feature: | Working Papers |
The era of paternalistic medicine has passed, but the notion that patients can act as consumers and make appropriate decisions concerning medical treatment poses countervailing risks of its own. A better accommodation among key players needs to be struck to foster the safe use of pharmaceuticals, according to HBS professor Arthur Daemmrich. The "pharmacy to the world," once located at the intersection of Germany, Switzerland, and France, today is found in the United States. Studies of the industry have attributed this sustained competitive advantage to a variety of factors, including U.S. intellectual property policies, funding for biomedical research through the National Institutes of Health, the absence of government controls on drug prices, and the availability of venture capital and other factors that fostered the growth of the biotechnology industry. The data and analysis presented in this working paper, however speculative, are an initial step toward deepening the understanding of interrelationships between government regulation, patients' mobilization both as regulators and as consumers, and the functioning of the pharmaceutical industry.
Published in 2008
Competition in Modular Clusters
| Authors: | Carliss Y. Baldwin and C. Jason Woodard |
|---|---|
| Published: | January 17, 2008 |
| Paper Release Date: | December 2007 |
| Feature: | Working Papers |
The last 20 years have witnessed the rise of disaggregated "clusters," "networks," or "ecosystems" of firms in a number of industries, including computers, telecommunications, and pharmaceuticals. In these clusters, different firms design and produce the various components of a complex artifact (such as the processor, peripherals, and software of a computer system), and different firms specialize in the various stages of a complex production process. This paper considers the pricing behavior and profitability of these so-called modular clusters. Baldwin and Woodard isolate the offsetting price effects in a model, and show how they might operate in large as well as in small clusters.
Published in 2005
New Learning at American Home Products
| Published: | April 25, 2005 |
|---|---|
| Feature: | Research & Ideas |
In Alfred D. Chandler Jr's new history of the modern chemical and pharma industries, American Home Products follows a singular path to success. An excerpt from Shaping the Industrial Century.
Published in 2004
Do Managers' Heuristics Affect R&D Performance Volatility? A Simulation Informed by the Pharmaceutical Industry
| Authors: | Francesca Gino and Gary P. Pisano |
|---|---|
| Published: | July 5, 2006 |
| Paper Release Date: | December 2004, revised February 2006 |
| Feature: | Working Papers |
Can the R&D process be managed to provide more certainty and success? The authors explore R&D performance volatility using the pharmaceutical industry as the model. The study looks at two types of heuristics that are commonly used to manage R&D project portfolios: (1) which products to start, and whether to continue or kill a product in development; (2) how resources should be allocated at each phase of development. By changing the heuristics used to make decisions at each stage of development, managers can decrease the amount of uncertainty and failure in the R&D process.
Side Effects: The Case of Propecia
| Published: | November 22, 2004 |
|---|---|
| Feature: | Research & Ideas |
Selling Propecia was a difficult marketing task for Merck & Co., and was recently the subject of a case study debated by Harvard Business School alumni.
Published in 2003
Why Europe Lags in Pharmaceuticals and Biotech
| Published: | December 8, 2003 |
|---|---|
| Feature: | Research & Ideas |
Governmental, cultural and academic differences are hurting Europe’s chances of gaining on the U.S. Can anything be done?
Sometimes Success Begins at Failure
| Published: | December 1, 2003 |
|---|---|
| Feature: | Research & Ideas |
Projects that appear to be duds may have unintended upsides—Viagra started life and failed as a drug for hypertension. Here are tips for turning negative test results into gold.
